

CHLORELLA PREPARATIONS EXHIBITING IMMUNOMODULATING PROPERTIES**REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of U.S. Provisional Application No. 60/224,014, filed August 10, 2000, 5 the content of which is herein incorporated by reference.

FIELD OF INVENTION

The present invention relates to *Chlorella* extracts for use as immunomodulators.

BACKGROUND OF THE INVENTION

10 *Chlorella* is a unicellular green algae that has been called a sun-powered supernutrient. Attested beneficial properties of this edible microalgae include wound healing, detoxification, constipation relief and growth stimulation. A number of studies have also indicated that *Chlorella* has 15 beneficial effects on the immune system, both *in vitro* and *in vivo*.

Chlorella occurs in both fresh water and marine water. Species of the *Chlorella* genus exhibit striking diversity of physiological and biochemical properties (Kessler, 20 E. "Phycotalk" 1989, 1:141-153; V. Rastogi Publ., New Delhi, India). *Chlorella* produces little cellulose and other indigestible cell wall material, and hence has been extensively investigated as a possible new source of food, especially as feedstock (Lee, Robert E. "Phycology" 2nd edition; 1989, page 25 281; Cambridge University Press).

Chlorella has the highest content of chlorophyll of any known plant. It also contains vitamins, minerals, dietary fibre, nucleic acids, amino acids, enzymes, etc. It contains more than 9% fats (out of which polyunsaturated fatty acids

[PUFA] represent about 82%). The vitamin content consists of provitamin A, vitamins B₁, B₂, B₆, niacin, B₁₂, biotin, vitamin C, vitamin K, pantothenic acid, folic acid, choline, lipoic acid, ionositol, PABA etc. Among the minerals present the most important are P, K, Mg, S, Fe, Ca, Mn, Cu, Zn and Co. The main components of *Chlorella* cells are about 60% protein (composed of all basic amino acids), and 20% carbohydrate.

Aqueous extracts of *Chlorella pyrenoidosa* has been used for its nutritive content as well as for other health benefits. Studies report on numerous health benefits including improved immune system function and detoxification of harmful toxins. It was introduced as a health food in the USA in 1977 when novel technology processes were developed which made it more digestible and has been the largest selling health food supplement in Japan for a number of years. The Taiwan *Chlorella* company is the world's largest supplier of *Chlorella*, and sells the product worldwide to Asia, Europe and North America, under the following brand names: *Algea*, *Bio-REU-RELLA*, *Green Gem*, *Green Boost*, *Green Nature*, *Green Power*, *Joyau Vert* and *Natural Boost*.

A number of studies have documented *C. vulgaris* extracts which have anti-tumor activity, as well as activity against *Listeria* and *E. coli* (Tanaka et al. *Immunopharmacol. Immunotoxicol.*, 1990, 12(2):277-291; Tanaka et al. *Cancer Immunol. Immunother.*, 1998, 45(6):313-320; Hasegawa et al. *Int. J. Immunopharmacol.*, 1990, 12(8):883-891). These activities appear to be immune-mediated rather than direct toxicity against the tumor or pathogen.

A number of *Chlorella* extracts are available commercially, including products by Swiss Herbal and Nature's Way. The Swiss Herbal product is identified as pure *Chlorella*

broken cells containing Protein 61%, Carbohydrate 21.1%, Fat 11.0%, Chlorophyll 2.866%, RNA 2.94% and DNA 0.28%.

Other publications related to the present field include the following:

5 Japanese patent application laid open No. Sho 58-15920 discloses polysaccharides from fresh water Chlorella having immune potentiator and anti-tumor activity.

Neveu et al. Experientia, 1978, 34(12):1644-1645 discloses that *C. pyrenoidosa* is an immune response modulator.

10 Vermeil and Morin CR Seances Soc. Biol. Fil., 1976, 170(3):646-649 discloses that *C. pyrenoidosa*, presumably by nature of its cell wall, protects mice against sarcoma grafting.

15 Miyazawa et al. J. Ethnopharmacol., 1988, 24(2-3):135-146 discloses that *C. pyrenoidosa* cells or extract mediate host immune enhancement of the anti-tumor response.

Umezawa et al. Chemotherapy, 1982, 30(9):1041-1046 and Komiyama et al. Chemotherapy, 1986, 34:302-307 disclose that the acidic polysaccharide Chlon A from *C. pyrenoidosa* has 20 immune enhancing and anti-tumor effects. Chlon A contains rhamnose, arabinose, glucose, galactose and glucuronic acid.

White and Barber Biochimica Biophysica Acta, 1972, 264:117-128 discloses an 88 kDa acidic polysaccharide from *C. pyrenoidosa* containing mainly rhamnose, as well as 25 arabinose, galactose, xylose, mannose and glucuronic acid.

US Patent No. 4,533,548 discloses acidic polysaccharide CH-1 from *C. pyrenoidosa* containing mainly rhamnose, as well as arabinose, galactose, glucose and

glucuronic acid. The polysaccharide was obtained via gel filtration with Sephadex G-75.

US Patent No. 4,831,020 discloses a polysaccharide extract from *C. minutissima*, a marine *Chlorella*, with immune-stimulating and anti-tumor activity. This patent states that polysaccharides from marine *Chlorella* species are more effective in activating immunity than fresh water *Chlorella* species. The polysaccharide extract was obtained via gel filtration with Sephadex G-50.

US Patent No. 4,786,496 discloses a lipid and glycolipid fraction of marine *Chlorella* with immuno-potentiating activity.

Kojima et al. J. Retic. Soc., 1973, 14:192-208 discloses a 1,250-1400 Da reticuloendothelial system (RES)-active glucan from *Chlorella*.

US Patent No. 3,462,412 discloses a process for preparing a RES-stimulating extract from *Chlorella*.

Japanese patent application, publication no. 06248003 discloses a *Chlorella* extract of 15 to 25 kDa, comprising polysaccharides containing predominantly galactose, with anti-neoplastic activity.

Mizuno et al. Bull. Fac. Agr. Shizuoka Univ. (Shizuoka Daigaku Nogakubo Kenkyu Hokoku), 1980, 30:51-59 discloses two fractions of neutral glycans from *Chlorella*, both apparently of small molecular weight.

Ukai et al. Ann. Proc. Gifu Pharm. Univ. (Gifu Yakka Daigaku Kiyo), 1990, 39:44-48 discloses two polysaccharides, CP-I and CP-II, from *C. pyrenoidosa* with RES-stimulating activity. CP-I comprises glucose, fucose, rhamnose, galactose

and mannose; CP-II comprises glucose, galactose, rhamnose and mannose.

Chu et al. Aquaculture, 1982, 29(3-4):241-252 discloses that the polysaccharide, ethanol-precipitable fraction of five algal species including *Chlorella* contains principally glucose, mannose, ribose/xylose, rhamnose and fucose.

SUMMARY OF THE INVENTION

Chlorella extracts prepared according to the invention show immune stimulatory activity in pharmacological and clinical tests. In one aspect, the extracts provided by the present invention have a higher immune stimulatory activity than extracts prepared and used in the art.

In one aspect, the invention provides preparations comprising high molecular weight *Chlorella* polysaccharide and polysaccharide complexes. The high molecular weight polysaccharide and polysaccharide complexes are about 1×10^5 Da to about 1×10^7 Da and constitute at least 22% (w/w) of the total *Chlorella*-derived content of the extract. In a preferred embodiment, the extract is derived from *Chlorella pyrenoidosa*.

The high molecular weight polysaccharide and polysaccharide complexes may be of a selected range, e.g. about 1×10^5 Da to about 3×10^5 Da, about 3×10^5 Da to about 5×10^5 Da, about 5×10^5 Da to about 6×10^5 Da, about 6×10^5 Da to about 7×10^5 Da, about 7×10^5 Da to about 8×10^5 Da, about 8×10^5 Da to about 9×10^5 Da, about 9×10^5 Da to about 1×10^6 Da, about 1×10^6 Da to about 2×10^6 Da, about 2×10^6 Da to about 3×10^6 Da, about 3×10^6 Da to about 4×10^6 Da, about 4×10^6 Da to about 5×10^6 Da, about 5×10^6 Da to about 7×10^6 Da, about 7×10^6 Da to about 9×10^6 Da, and about 9×10^6 Da to about 1×10^7 Da.

The extracts may contain various different percentages of polysaccharide and polysaccharide complexes as a fraction of the total Chlorella-derived content of the extract. The percentage may be at least 24% (w/w), at least 26% (w/w), 5 at least 28% (w/w), at least 30% (w/w), at least 35% (w/w), at least 40% (w/w), at least 45% (w/w), at least 50% (w/w), or at least 60% (w/w).

In another aspect, the high molecular weight polysaccharide and polysaccharide complexes contain glucose and 10 any combination of: galactose, rhamnose, mannose and arabinose.

In another aspect, the high molecular weight polysaccharide and polysaccharide complexes is substantially free of ribose, nucleic acids, ribonucleic acids and unassociated proteins. The high molecular weight 15 polysaccharide and polysaccharide complexes may also contain N-acetyl glucosamine and N-acetyl galactosamine.

In another aspect, the extracts of the invention retain immunomodulating activity upon treatment to remove unassociated DNA, RNA and proteins. Such treatment includes 20 digestion by pronase, DNase, RNase and proteases.

In another aspect, the extracts of the invention retain immunomodulating activity upon treatment to effect cleavage of specific glycosidic linkages, the linkages being defined by their susceptibility to cleavage by amylase, 25 amyloglucosidase, cellulase or neuraminidase. Such susceptible linkages are typically:

- (i) three or more α -1,4-linked D-glucose units;
- (ii) α -1,4-linked glucosides;
- (iii) α -1,4-linked galactosides; or

(iv) α -1,4-linked D-glucose.

The invention also provides nutritional compositions containing the high molecular weight *Chlorella* extract with at least one energy source which may be carbohydrates, fats or 5 nitrogen.

The extracts of the invention may also be used in combination or in mixture with a conventional supplement such as vitamin E, vitamin C and folic acid. The extracts may also be used with other nutraceuticals such as fish oils, spirulina 10 and echinacea, especially those nutraceuticals which have immunostimulant activity.

The invention also provides a process for obtaining *Chlorella* preparations having immunomodulating activity. The process contains the steps of:

15 (a) size fractionating an aqueous extract of *Chlorella*, and

(b) selecting fractions comprising high molecular weight polysaccharide and polysaccharide complexes of about 1×10^5 Da to about 1×10^7 Da.

20 The process for obtaining the *Chlorella* extract may further include the step of pooling and concentrating the selected fractions. Size fractionation may be achieved by chromatography, ultrafiltration or ultracentrifugation.

The invention also provides a method for modulating 25 the immune response of a mammal including humans by administering to the mammal an effective amount of the high molecular weight *Chlorella* extract. Such modulation includes increased proliferation of splenocytes and increased production of cytokines such as IL-6, IL-10, INF- γ and TNF- α , and may be

advantageously used to treat or prevent bacterial or fungal infections.

The extract may further be administered as a supplement to a vaccination regimen to further stimulate the 5 immune response. A flu vaccine may be advantageously used with the extract. The extract may be present as an adjuvant to the vaccines, especially as an oral vaccine adjuvant.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention in its various embodiments will now be 10 described with reference to the attached drawings.

Figure 1: Combination size-exclusion chromatography (SEC) / refractive index detection (RI) / multi-angle laser light scattering (MALS) chromatogram of immune booster preparations IBP-1 or IBP-2. The top trace is the RI 15 chromatogram; the bottom trace is the MALS response;

Figure 2: Cumulative molecular weight profile of IBP-1;

Figure 3: SEC chromatogram of IBP-2 using Sephadryl S 1000 SF;

20 Figure 4: SEC chromatogram of IBP-2 (or IBP-1) using Sephadryl S 300 HR;

Figure 5: Stimulation of splenocyte proliferation by various Chlorella extract fractions resolved by Sephadryl S 300 HR; IBP-6s is the peak shoulder fraction of IBP-6; 'Cells' 25 and 'Cells+DMSO' are negative controls; LPS is lipopolysaccharide, used as a positive control;

Figure 6: Stimulation of splenocyte proliferation by various Chlorella extract fractions resolved by Sephadex G100

chromatography of IBP-2; 'Cells' is a negative control; LPS is a positive control;

Figure 7: Splenocyte proliferation - Titration curve of IBP-2; 'Cells' is a negative control; LPS is a positive control;

Figure 8: Proliferation assay measuring ^3H -incorporation by isolated B- or T-cells in the presence of 25 $\mu\text{g}/\text{mL}$ IBP-2;

Figure 9: Nitric oxide production by BALB/c inflammatory peritoneal macrophages cultured in the presence of various concentrations of IBP-2; 'IFN+LPS' is a positive control;

Figure 10: IL-6 production by BALB/c mouse spleen cells in the presence of various concentrations of IBP-2; 'Con A' is Concanavalin A; 'Cells+ConA' and 'Cells+LPS' are positive control samples, Concanavalin A is at 10 $\mu\text{g}/\text{mL}$; LPS is at 20 $\mu\text{g}/\text{mL}$;

Figure 11: Effect of IBP-2 compared to 4 mg echinacea (Echin.) on *Listeria monocytogenes* proliferation in mice;

Figure 12: Effect of IBP-2 compared to crude algae and echinacea on *Candida albicans* proliferation in mice;

Figure 13: Mouse splenocyte proliferation as measured by ^3H -incorporation, cultured in the presence of IBP-2 or commercial Chlorella extracts from Swiss Herbal and Nature's Way.

Figure 14: Capillary electrophoresis chromatogram of the dialyzed crude extract IBP-2. The monosaccharides are assigned to the peaks as follows: ribose at position 9.05;

rhamnose at position 10.47; mannose at position 10.68; galactose at position 11.14; and glucose at position 11.65.

Figure 15: Capillary electrophoresis chromatogram of the retained portion after IBP-2 was passed through a 1MDa MWCO 5 ultrafiltration membrane. The monosaccharides are assigned to the peaks as follows: N-acetyl galactosamine (GalNAc) at position 7.30; N-acetyl glucosamine (GlcNAc) at position 7.43; arabinose at position 10.52; rhamnose at position 10.90; mannose at position 11.11; (note that the peak at position 10 11.01 is a bubble; the mannose peak is just to the right of this peak); galactose at position 11.62; glucose at position 12.13.

Figure 16: DEAE Sepharose Fast Flow of IBP-2. A sample was applied on Pharmacia 1.0 x 30 cm column and eluted 15 with piperazine/HCl (0.02 M, pH 8.8) buffer at a rate of 5 mL/min. NaCl gradient was employed: 0-20% in 20 column volumes, then 20-100% in 2 column volumes.

Figure 17: DEAE Sepharose Fast Flow of retention portion after IBP-2 was passed through an ultrafiltration 20 membrane with MWCO 1MDa. A sample was applied on Pharmacia 1.0 x 30 cm column and eluted with piperazine/HCl (0.02 M, pH 8.8) buffer at a rate of 5 mL/min. NaCl gradient was employed: 0-20% in 20 column volumes, then 20-100% in 2 column volumes.

25 **DETAILED DESCRIPTION OF THE INVENTION**

The present invention relates to a method for enhancing immunity defence mechanisms of mammals including humans. Immunity defences are enhanced by the administration of Chlorella-derived immunomodulators in the form of Chlorella-30 derived extracts of molecular weights between 1×10^5 Da and 1×10^7 Da.

A. Chlorella

Species of the *Chlorella* genus used in the invention includes the following: *minutissima*, *marina*, *salina*, *pyrenoidosa*, *vulgaris*, *anitrata*, *antarctica*, *autotrophica*,
5 *regularis*, among others (see World Catalog of Algae, 2nd Edition, pages 58-74; Miyachi et al. (Eds); 1989; Japan Scientific Societies Press, the content of which is herein incorporated by reference).

Mutant strains of *Chlorella*, either naturally
10 occurring or artificially produced, for example by irradiation (e.g. ultraviolet, X-ray), chemical mutagens or by site-directed mutagenesis, are within the scope of the invention. In one embodiment, *C. pyrenoidosa* and its variants are preferred. In another embodiment, *C. ellipsoidea* and its
15 variants are preferred. Cultivation of *Chlorella* is carried out by methods known in the art using suitable media and culture conditions (see for example, White and Barber, *Biochimica Biophysica Acta.*, 1972, 264:117-128). Polysaccharide production may be influenced by physiological
20 and metabolic manipulation. Composition of the growth media may influence growth rate leading to changes in cell wall thickness. Genes responsible for growth may be up- or down-regulated. For a method used to transform eukaryotic algae, see for example US patent 6,027,900; for methods to select
25 algal mutants, see for example US patent 5,871,952. Thus, by selection under various conditions, variants of biopolymer immunomodulators from *Chlorella* may be manufactured.

B. Chlorella extracts and their preparation(a) Preparation of crude extract:

30 Crude aqueous extracts of *Chlorella* are prepared by methods known in the art, including hot water extraction of

cultured cells or spray dried cells (US 4,831,020 and US 5,780,096) and solvent extraction methods (White and Barber, Biophys. Biochim. Acta, 1972, 264:117-128; US 3,462,412). Crude extracts may be obtained from the Taiwan Chlorella 5 company (www.taiwanchlorella.com/product-3.htm).

In one embodiment, the crude extract is prepared from spray-dried Chlorella cells with an average moisture content of 0.3%; (the moisture content was determined after drying the spray-dried material for 16 h under a vacuum of 5 mm). The 10 crude extract is prepared by treating the cells with aqueous media, preferably water or weak solutions of organic acids, such as acetic acid, ascorbic acid, benzoic acid, citric acid, lactic acid, maleic acid, propionioic acid, sorbic acid, succinic acid etc., preferably benzoic acid, under gentle 15 agitation. The extraction process could be executed at various temperatures ranging from 0 to 100°C, preferably between 50 and 90°C. The yields and immunoactivity correlating with chromatographic profiles indicate that 1 h at 80°C is a suitable combination of time and temperature to perform this step 20 efficiently.

The residual cells and the cell debris were separated by centrifugation with a relative centrifugal force (RCF) of 150 to 10,000 g, preferably 4,000 to 10,000 g. The time necessary to complete this step is in relation to the 25 centrifugal force; 20 min. is sufficient at 10,000 g. The supernatant was then micro-filtered. Alternatively, filtration may be used to remove whole cells and debris, in which case use of a series of filters starting from coarse, through medium and ending with micro-filtration, is necessary. Cross-flow 30 filtration or vibrating membrane technology is recommended to reduce fouling. Filtration is particularly sensitive to temperature and time period required for extraction. Centrifugation is therefore the preferred route.

After centrifugation or filtration, the supernatant (or filtrate) may be dried to obtain IBP-1 products in dry form. The drying was achieved by lyophilization, cold air-flow, or preferably by spray-drying. Alternatively, the volume 5 of the extract could be reduced first (to 10-50%, preferably 20%), and then the active materials precipitated from the solution with suitable precipitants, preferably ethanol or ammonium sulfate.

IBP-1 was liberated from salts and low molecular mass 10 products. Although a variety of aqueous media (such as diluted alcohols, various buffers, diluted acetic acid, etc.) could be employed, water was found to be a sufficient medium for the dialysis. This step reduced the mass of the extracted material by about 50% and increased its specific immunoactivity (as 15 judged by effect on stimulation of splenocytes, see below) by about 25%. Dialysis could be replaced by desalting with gel filtration media, such as Sephadex G 25, Bio Gel P 6 or equivalents. Similarly, corresponding ultrafiltration membranes with corresponding molecular weight cut-offs could be 20 used. After the desalting step, the material (IBP-2) may be dried using methods described for IBP-1.

(b) Size fractionation of extracts:

Size fractionation of *Chlorella* extracts can be accomplished by any method known in the art, including size 25 exclusion chromatography, sedimentation analysis e.g. gradient centrifugation, and ultra-filtration.

IBP-1 or IBP-2 is a mixture of polysaccharides and polysaccharide complexes, with average molecular mass of the immunomodulatory fraction of interest ranging from 100 up to 30 10,000 KDa. Polysaccharide complexes are polysaccharides which are non-covalently associated with a non-polysaccharide

biopolymer which, by itself, has no significant immune activity. Non-polysaccharide biopolymers include DNA and protein which may contribute to the cumulative molecular weight of the extract but which has no significant immune activity.

5 In various embodiments, the high molecular weight polysaccharide and polysaccharide complexes are about 1×10^5 Da to about 1×10^5 Da, about 3×10^5 Da to about 5×10^5 Da, about 5×10^5 Da to about 6×10^5 Da, about 6×10^5 Da to about 7×10^5 Da, about 7×10^5 Da to about 8×10^5 Da, about 8×10^5 Da
10 to about 9×10^5 Da, about 9×10^5 Da to about 1×10^6 Da, about 1×10^6 Da to about 2×10^6 Da, about 2×10^6 Da to about 3×10^6 Da, about 3×10^6 Da to about 4×10^6 Da, about 4×10^6 Da to about 5×10^6 Da, about 5×10^6 Da to about 7×10^6 Da, about 7×10^6 Da to about 9×10^6 Da, and about 9×10^6 Da to about
15 1×10^7 Da.

Size fractionation to obtain the above fractions is based on principles of molecular sieving. Typically, size exclusion chromatography techniques and ultrafiltration methods are employed. The basic principles of size exclusion
20 chromatography are well known to those in the art, and are explained in "Gel filtration: Principles and Methods. Eighth edition, Amersham Pharmacia Biotech AB, Rahhms I Lund, Uppsala, Sweden". The appropriate columns for fractionating particular ranges can be readily selected and effectively used to resolve
25 the above fractions, e.g. Sephadryl S 100 HR, Sephadryl S 200 HR, Sephadryl S 300 HR, Sephadryl S 400 HR and Sephadryl S 500 HR or their equivalents. In an analogous fashion, Sepharose media or their equivalents, e.g. Sepharose 6B, 4B, 2B, could be used.

30 Purification of the polysaccharides or polysaccharide complexes with protein could be achieved in combination with other chromatography techniques, including affinity

chromatography, ion exchange, hydrophobic interaction chromatography etc. An example of IBP-2 (the retainate after IBP-2 was passed through ultrafiltration membrane with MWCO > 1 MDa) chromatography using DEAE-Sepharose Fast Flow 5 anion exchange chromatography is given in Figures 16 and 17. The figures demonstrate significant decrease in the protein content after IBP-2 was passed through the ultrafiltration membrane.

Ultrafiltration of the samples could be performed 10 using molecular membranes with appropriate molecular mass cut-offs. The specific membranes and procedures used to effect fractionation are widely available to those skilled in the art, as outlined in
http://www.uku.fi/laitokset/anat/PG/c_method.htm.

15 In one embodiment, the method used for characterising and quantifying these materials is based on combined size exclusion chromatography (SEC) / multi-angle laser light scattering (MALS) / refractive index detection (RI). In the hybrid technique (SEC/MALS/RI), an isocratic HPLC experiment 20 using a Tosohaas GMPWXL SEC column is used to separate mixtures according to molecular size. On-line MALS determines the average molecular weight distribution of the eluting biopolymers and hence provides specificity in the analysis. RI detection is used both for quantification and to provide the 25 elution profile required in processing the MALS data.

An example of the SEC chromatogram obtained for a typical extract is shown in Figure 1. The top trace is the chromatogram recorded using the RI detector while the bottom trace is the MALS response at one of the detectors (90 30 degrees). The MALS peak is a maximum for the high molecular mass component which actually corresponds to a small percentage of the total extract as can be seen from the upper trace.

Thus, although the molecular weight range extends from a few KDa to about 10 MDa, the weight average molecular weight (MW) for the entire extract is determined to be around 90 kDa. This can be seen most clearly from the cumulative molecular weight
5 profile of IBP-1 (Figure 2).

IBP-1 or IBP-2 can be further fractionated using suitable chromatographic or ultrafiltration techniques. Size exclusion chromatography matrices with wide fractionation range such as Sephadryl S 1000 SF (Figure 3) resolved the extract
10 into two peaks: the first eluted just after the void volume; its average molecular mass, as measured by MALS, averaged 1,000 KDa; the second peak eluted just after the first peak. The combined fractions representing the first peak were desalted and dried analogously to that of IBP-1, resulting in
15 IBP-3. This material was superior in its immunoactivity compared to the second peak (IBP-4). Aqueous media were used in this chromatography procedure, preferably 0.15 M NaCl. Although IBP-1 exhibited higher immunoactivity than the IBP-2,
the difference was insignificant. The contribution to the
20 immunostimulant activity (increasing gradually with mass) starts levelling off when molecular mass reaches around 500 KDa.

IBP-4 could be further fractionated using suitable chromatographic or ultrafiltration techniques. Both ion
25 exchange chromatography (IEC) and SEC were found to be useful for further resolution of IBP-4. SEC matrices with the appropriate fractionation range, for example Sephadryl S 300, could be used. Sephadryl S 300 HR resolved IBP-1 or IBP-2 into two peaks (Figure 4). The first peak started eluting in the
30 very last fractions of the void volume of the column. The majority of the eluted biopolymers exhibited molecular masses ranging from 100 to 500 KDa. The combined fractions representing the first peak were desalted and dried analogously

to that of IBP-1, resulting in IBP-5. This material was superior in its immunoactivity to the second peak (IBP-6) which eluted just after the first peak touched the baseline (Figure 5). IBP-5 represented typically only 30% of the combined mass of both peaks. Aqueous media were used for this chromatography procedure, preferably a 0.1M acetate, pH 4.5 buffer with linear NaCl gradient. The difference in the immunoactivity of IBP-5 and IBP-6 was higher than in that between IBP-3 and IBP-4; typically the ratio of CPM_{IBP-3} to CPM_{IBP-4} was 5:2, as measured by the level of ³H-incorporation into proliferating splenocytes. The process could be, to some extent, simplified by use of ultrafiltration membranes with molecular mass cut-off of about 500 KDa. For instance, Omega ZM 500 membrane successfully could be used.

IBP-6 could be further fractionated using suitable chromatographic or ultrafiltration techniques, for instance using chromatographic matrices such as Sephadex G 100, Sephadex G 75 or analogous media or corresponding ultrafiltration membranes. However, specific immunoactivity residing in IBP-6 was significantly weaker than that of IBP-3 and IBP-5, and therefore was not of prime interest. However, Sephadex G 100 could be efficiently used to remove from IBP-2 the majority of lower molecular weight material (IBP-8), which is associated with low immunoactivity (Figure 6). Typically the ratio of CPM_{IBP-7} to CPM_{IBP-8} was 10:1; (IBP-7 being the high molecular mass and immunoactive fraction). This purification step could be achieved just as well with a YM-100 ultrafiltration membrane.

Crude extracts of *Chlorella* contain about 61% protein and 21% carbohydrate. Processing of *Chlorella* according to the present invention results in a higher percentage of polysaccharide and polysaccharide complexes, i.e. the extracts of the invention have a higher percentage of polysaccharide and

polysaccharide complexes relative to the total material derived from *Chlorella*, compared to a crude extract from broken cells. It is understood that materials unrelated to *Chlorella* may be added to the *Chlorella* extract and that such extracts are
5 within the scope of the invention.

The percentage of polysaccharide and polysaccharide complexes in the extracts of the invention is at least 23% (w/w) of the total *Chlorella*-derived content of the extract. In various embodiments, the percentage is at least
10 24% (w/w), at least 26% (w/w), at least 28% (w/w), at least 30% (w/w), at least 35% (w/w), at least 40% (w/w), at least 45% (w/w), at least 50% (w/w), or at least 60% (w/w).

The high molecular weight polysaccharide and polysaccharide complexes may be further purified and isolated
15 to the various percentages indicated above by removal of non-polysaccharide components. Such non-polysaccharide components include DNA, RNA and unassociated proteins. (Unassociated proteins are defined for the purpose of the present application as proteins which are not associated with polysaccharides in a
20 polysaccharide complex).

One method of removal is the use of digestion enzymes to cleave the non-polysaccharide components, followed by size fractionation to remove the cleaved products as described in the Examples below (Example 7). Digestion enzymes include
25 pronase, ribonuclease, DNase and proteases, as well known in the art and described in various text books, one example of which is Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. Proteases useful for digestion of
30 unassociated proteins include: endo- and exopeptidases, pronase, serine proteases such as trypsin, chymotrypsin and

subtilisin, thiol proteases such as papain, and calcium-requiring proteases such as thermolysin.

Alternatively, non-polysaccharide components may be removed by affinity chromatography, for example by use of DNA-
5 or RNA-binding matrices (Maniatis et al., 1982). Another option is to purify the polysaccharide and polysaccharide complexes away from the contaminating components by use of polysaccharide binding matrices such as lectins. In another embodiment, the extracts of the invention may be treated with
10 glycosidic enzymes under conditions and for a length of time sufficient to effect cleavage of:

- (i) three or more α -1,4-linked D-glucose units;
- (ii) α -1,4-linked glucosides;
- (iii) α -1,4-linked galactosides; or
- 15 (iv) α -1,4-linked D-glucose.

Examples of glycosidic enzymes useful for cleavage of such glycosidic linkages include: amylase, amyloglucosidase, cellulase and neuraminidase.

C. Characterization of extracts

20 Carbohydrate composition, DNA content and amino acid composition of the *Chlorella* extracts of the invention can be determined by any suitable method known in the art.

Immune activity of the extracts of the invention are associated with high molecular weight *Chlorella*
25 polysaccharides, defined as those macromolecules consisting of monosaccharides joined by glycosidic linkages. The polysaccharides are present in the extracts in the form of free polysaccharides or complexed polysaccharides (i.e.

polysaccharides which are non-covalently associated with a non-polysaccharide biopolymer which, by itself, has no significant immune activity). In one embodiment, the protein content of the extract is about 20% to 50%, preferably 20% to 30%. Of 5 this percentage of proteins, about 40% to 60% are associated with polysaccharides.

Non-polysaccharide biopolymers include DNA, protein and possibly RNA, which may contribute to the cumulative molecular weight of the extract but which has no significant 10 immune activity. Unassociated RNA, DNA and protein, i.e. those not complexed with the polysaccharides, do not contribute significantly to immune activity of the extracts. For the purposes of the present application, unassociated RNA, DNA and protein are defined functionally as those RNA, DNA and protein 15 which are susceptible to cleavage by ribonuclease (RNase), deoxyribonuclease (DNase) and common proteases of the serine and thiol class. The extracts of the present invention may thus be essentially free or substantially free of unassociated RNA, DNA and protein. By "essentially free" is meant less than 20 5% unassociated DNA or RNA and less than 15% unassociated proteins. By "substantially free" is meant less than 2% associated DNA or RNA and less than 10% unassociated proteins.

It is understood that, while the non-polysaccharide biopolymers *per se* lack immune activity, their association with 25 the polysaccharides may contribute to the immune activity of the polysaccharides since the non-polysaccharide biopolymers of the complex may fulfill certain steric or polar requirements which enable the polysaccharides to function effectively as immunomodulators.

The extracts of the present invention may be digested 30 with amylase, amyloglucosidase, cellulase and neuraminidase without significant loss of immune activity. Immune activity

thus apparently resides in polysaccharides or their complexes which do not contain a substantial amount of three or more α -1,4-linked D-glucose units; α -1,4-linked glucosides; α -1,4-linked galactosides; or α -1,4-linked D-glucose. However,
5 it is understood that immunomodulatory polysaccharides may contain the above glycosidic linkages if such linkages are not accessible to enzyme digestion.

D. Uses of extracts

Biological response modifiers have been defined as
10 those agents that modify the host's biological response by a stimulation of the immune system, which may result in various therapeutic effects. One of the categories of substances belonging to this class is immunomodulators. As used herein, the term "immunomodulator" refers to an agent which is able to
15 modulate an immune response. In the context of the present invention, such modulation is an enhancement of the host's immunity defence mechanism.

Chlorella extracts are thought to be primarily a B-cell and macrophage stimulator. One benefit of B-cell
20 immunomodulators is that they can stimulate immune function in those who may have an impaired antibody response to an antigen. Also, a B-cell stimulator might increase the rapidity of the antibody immune response when presented with a new infection. *Chlorella* extracts provide a safe, efficacious and cost
25 effective alternative for preventative health treatment.

In vitro studies demonstrated that *Chlorella* extracts stimulated proliferation of BALB/c mouse spleen cells, and macrophage production of IL-6 and NO₂. *Chlorella* extracts were also examined *in vivo*, and found to significantly reduce
30 infection with *Listeria monocytogenes*, as well as the fungus *Candida albicans* (see Examples 8 to 13).

A series of three toxicology trials have been completed for *Chlorella* extracts. No effect of *Chlorella* extract administration was evident during the 28-day oral toxicity study in rats. For the acute oral toxicity in rats,

5 to determine the highest non-lethal or the lowest lethal dose of the product following a single oral administration, the study found that the lowest lethal dose of a crude *Chlorella* extract was in excess of 2000 mg/kg body weight. The bacterial mutation assay showed that *Chlorella* extracts did not exhibit

10 any mutagenic activity under the test conditions.

A recently completed randomized, double-blind placebo-controlled study found that *Chlorella* extracts demonstrated significant immunostimulatory effects in healthy adults receiving the influenza vaccine, compared to placebo

15 subjects (see Example 14).

In vitro experiments with human blood cells show stimulation of production of interleukins, similar to that seen in the mouse model.

Chlorella extracts of the invention are suitable for

20 use in any condition or disease state where immune response enhancement or modulation is desired. In one embodiment, *Chlorella* extracts may be used in an effective amount as adjuvants in various forms of mucosal vaccine preparations, especially for oral administration.

25 Adjuvants may protect the antigen from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system. Known adjuvants for mucosal administration

30 include bacterial toxins, e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile*

toxin A and the *pertussis* toxin (PT). *Chlorella* extracts, being an edible product of high molecular weight and themselves immune stimulants, are candidates for use as adjuvants in oral vaccines.

5 The term "effective amount" of an immunomodulator refers to an amount of an immunomodulator sufficient to enhance a host defence mechanism. This amount may vary to some degree depending on the mode of administration, but will be in the same general range. If more than one immunomodulator is used
10 (for example, *Chlorella* extract in combination with echinacea), each one may be present in these amounts or the total amount may fall within this range. The exact effective amount necessary could vary from subject to subject, depending on the species, age and general condition of the subject, the severity
15 of the condition being treated, the mode of administration, etc. Thus, it is not possible to specify an exact effective amount. However, the appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation or prior knowledge in the
20 immunomodulator art.

The term "treatment" as used herein covers any treatment of a mammal, particularly a human, and includes:

(i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet
25 been diagnosed as having it;

(ii) inhibiting the disease, i.e., arresting its development; or

(iii) relieving the disease, i.e., causing regression of the disease.

E. Form of extracts

The nutritional and pharmaceutical compositions containing *Chlorella* extracts of the invention may be formulated and administered in any form suitable for enteral administration, for example oral administration or tube feeding. The formulations are conveniently administered in the form of an aqueous liquid. The formulations suitable for enteral application are accordingly preferably in aqueous form or in powder or granulate form, including tablet form. The powder or granulate may be conveniently added to water prior to use. In liquid form, the compositions have a solid content of typically from 0.1% to 50% by weight, preferably from 1% to 10% by weight. As a drink, the compositions may be obtained by any manner known, e.g. by admixing the *Chlorella* extract with an energy source such as carbohydrates, fats and nitrogen sources.

The nutritional compositions may be in the form of a complete formula diet (in liquid or powder form), such that when used as sole nutrition source, essentially all daily caloric, nitrogen, fatty acids, vitamin, mineral and trace element requirements are met. However, the nutritional compositions of the invention are preferably intended for use as a dietary supplement.

Pharmaceutical compositions of the invention may also be formulated in a single-dose format, where they comprise *Chlorella* extracts and a pharmaceutically acceptable carrier. Such pharmaceutical compositions are suitable for enteral administration, such as oral, nasal or rectal administration. Suitable compositions may be in liquid form or solid form. Dosage of liquid compositions are typically from 0.1% to 50% by weight, preferably from 1% to 10% by weight of *Chlorella* extract. Dosage of solid compositions are typically from 0.2 mg/kg to 200 mg/kg, preferably from 1 mg/kg to 10 mg/kg of

Chlorella extract The compositions may be in the form of tablets, hard and soft capsules, and sachets.

Suitable carriers are known in the art. They comprise fillers such as sugars or cellulose, binders such as 5 starch, and disintegrators if required.

The following examples are offered by way of illustration and not by way of limitation.

Example 1: Preparation of IBP-1.

Twenty grams of dried powder of *Chlorella pyrenoidosa* 10 were mixed with 100 mL distilled water and heated under gentle stirring for 1 h at 80°C. The material was centrifuged at 10,000g for 20 min; the residual pellet was washed twice. The combined supernatants were then micro-filtered and spray dried. The average yield was 10.5%. The extraction of the pellet for 15 1 h at 80°C could be repeated several times, preferably twice, instead of simple wash.

Alternatively, the combined supernatants were evaporated to 1/5 of their original volume using a rotary evaporator under reduced pressure, then precipitated with 20 ethanol (80% final ethanol content). The mixture was kept at 4°C for 18 h, then the precipitate was filtered off, washed with absolute ethanol and vacuum-dried.

Example 2: Preparation of IBP-2.

The extracted material, prepared as above, was 25 desalted by exhaustive dialysis against water at 4°C and then spray-dried. The average yield was about 7.5%.

Example 3: Chromatography of IBP-2 and preparation of IBP-3.

Twenty milligrams of IBP-2 were dissolved in 1 mL of distilled water, pre-filtered with a 0.45 μm filter and loaded on Sephadex G 1000 HR column (1.0 x 50 cm) and eluted with 0.15 M NaCl. Chromatography was monitored at 280 nm and at 490 nm after interaction of the eluted fractions with a phenol / sulfuric acid reagent. The mixture was resolved into two peaks. The major immunoactivity was in the high molecular mass peak (IBP-3). However, the lower molecular mass peak (IBP-4) also contained a significant portion of immunoactivity. The chromatogram is shown in Figure 3.

Example 4: Chromatography of IBP-2 and preparation of IBP-5.

Two hundred mg of IBP-2 were dissolved in 10 mL distilled water, pre-filtered with 0.45 μm filter, loaded on a Sephadex G 300 HR column (2.5 x 90 cm), and eluted with 0.1 M acetate buffer, pH 4.5 and linear NaCl gradient. Chromatography was monitored at 280 nm, and at 490 nm after interaction of the eluted fractions with a phenol/sulfuric acid reagent. The mixture was resolved into two peaks. The major immunoactivity was in the high molecular mass peak (IBP-5). The lower molecular mass peak (IBP-6) consisted of two fused peaks (an apparent peak shoulder; the fractions of which were tested as IBP-6s, Figure 5). The SEC profile is shown in Figure 4.

25 Example 5: Chromatography of IBP-2 and preparation of IBP-7.

Two hundred mg of IBP-2 were dissolved in 10 mL distilled water, pre-filtered with 0.45 μm filter, loaded on Sephadex G 100 column (2.5 x 90 cm), and eluted with 0.1 M acetate buffer, pH 4.5 and linear NaCl gradient. Chromatography was monitored at 280 nm, and at 490 nm after

interaction of the eluted fractions with a phenol / sulfuric acid reagent. The mixture was resolved into two peaks. The major immunoactivity was in the high molecular mass peak (IBP-7). The lower molecular mass peak (IBP-8) retained much less of the activity. IBP-9 represents the fractions following IBP-8 (Figure 6).

Example 6: Compositional analysis

Dialysis or ultrafiltration demonstrated that only a small portion of immunoactivity was associated with low molecular mass (less than 100 KDa) compounds. The active material is thermally stable and could be precipitated from solution with ethanol or ammonium sulfate. The thermal stability of the extract makes it suitable for spray-drying; indeed, immunomodulatory activity was retained after the spray-drying process. A typical protein content of a fraction is about 30%. DNA content varies from 0% to 20%, with 0% to 2% at molecular masses greater than 100 KDa.

(a) Carbohydrate composition by planar chromatography and gas chromatograph (GC) :

In one embodiment, the lyophilized extract (or further purified fractions) was dissolved in water (1 mg/mL, 400 µL) and hydrolysed with 1M trifluoacetic acid (TFA, 1 mL) at 100 °C, overnight with stirring, in tightly sealed 4 mL screw cap vials. The sample was then evaporated repeatedly to dryness using methanol. The dried hydrolysate was reduced using 0.5 M NaBH₄ in 1 M NH₄OH (0.6 mL) under overnight stirring at room temperature. The borohydride was then quenched with acidic methanol (20% acetic acid in methanol, 1 mL) and the mixture evaporated to dryness.

Three mL of acetic anhydride were added to the sample; the mixture was heated in a water bath to 80°C for 2h to produce acetyl alditols and then evaporated to dryness.

The acetyl alditol samples were extracted by 5 distributing the reaction mixture between ethyl acetate and water; the organic phase was used directly for gas chromatography/mass spectroscopy (GC-MS) analysis.

All standards and sample extracts were dissolved in ethyl acetate and concentrated to approximately 100 µL. 10 Samples were injected using the split mode of a Thermoquest Trace 2000 gas chromatograph at a 10:1 split and chromatographed on an SGE BPX70 capillary column (30 m x 0.25 mm x 0.25 µm film thickness). Helium carrier gas was used at a constant flow rate of 1.0 mL/min.

15 The gas chromatograph oven was programmed at an initial temperature of 190°C (hold for 1 minute) followed by a 3°C/minute ramp to 260°C (hold for 10 minutes at 260°C). The capillary column was interfaced directly to the mass spectrometer (Thermoquest GCQ ion trap), with the transfer line 20 temperature at 260°C. Using this oven program, all compounds of interest were found to elute within 20 minutes.

The mass spectrometer ion source was maintained at 150°C. Spectra were recorded from m/z 50 to 500 using both electron impact mode (70 eV) and chemical ionization (CI) mode 25 with ammonia reagent gas.

Retention times for the monosaccharides were established by derivatizing pure standards of individual sugars and/or chromatographing commercially available mixtures of alditol acetates (Supelco, Inc.). The sugars present in the 30 sample extracts were identified by comparison of retention

times and mass spectra against these standards. All samples with immunomodulatory activity contain glucose, galactose, rhamnose, mannose and arabinose. Extracts of molecular weight greater than 1×10^6 Da are substantially free of ribose.

5 (b) Monosaccharide compositional analysis using polyacrylamide gel electrophoresis (PAGE):

The standard hydrolysis protocols to release acidic, neutral or basic monosaccharides from the polysaccharide backbones were employed. The liberated monosaccharides were
10 labeled with fluorescent labeling reagent 2-aminoacridone (AMAC) first, followed by reduction of the formed Schiff base with sodium cyanoborohydride. Polyacrylamide gel electrophoresis of the mixtures was then run on gradient gels according the instruction manual. Hydrolysates produced from
15 IBP-2 contained glucose, galactose, rhamnose mannose, and arabinose. A substantial mount of ribose was also found. However, the hydrolysates produced by treatment of IBP-5 and IBP-7 with 2M TFA at 100°C for 5 h clearly contained only glucose and galactose as well as rhamnose, mannose and
20 arabinose. No ribose was found in these hydrolysates. This was in accord with our previous findings that RNA fragments of low molecular mass were present in IBP-2. However, because of their small size they could not be present in high molecular mass peaks of IBP-5 and IBP-7 obtained from Sephadex G 100 of
25 Sephacryl S 300 chromatographies, respectively. Another band placed between N-acetyl galactosamine (GalNAc) and mannose was detected in PAGE but could not be assigned to any of the conventional monosaccharides. The reaction mixtures obtained by hydrolysis performed under the conditions used for sialic
30 acid release (0.1 TFA, 80°C, 1 h) resulted in a product with a Rf identical with that of sialic acid and another major band with retention time significantly slower than that

corresponding to GalNAc. Four molar HCl hydrolysis for 3 h at 100°C (a condition for aminosugar release) resulted in PAGE in bands corresponding to GalNAc and N-acetyl glucosamine (GlcNAc). However judging from the intensity of other bands 5 they were insignificant components of IBP-5 of IBP-7.

(c) Monosaccharide compositional analysis using capillary electrophoresis(CE) :

The protocol followed was that of Sato *et al.* (Sato K., Okubo A., Yamazaki T., (1997) Determination of 10 monosaccharide derivatized with 2-aminobenzoic acid by capillary electrophoresis. Anal Biochem 251: 119-121). IBP-2 or its fractions were hydrolyzed first in 0.1 M TFA (1 mg/ml), at 100°C for 18h, the aqueous acid was removed under reduced pressure, the residual TFA was removed by a sequential 15 evaporation with methanol until dryness.

The crude extract IBP-2 contains primarily glucose and galactose; glucose is the most prevalent monosaccharide in the extract. Also present are rhamnose, mannose and arabinose, albeit in significantly smaller quantities (Figure 14). When 20 the extract was subjected to ultrafiltration using a 1 Mda MWCO membrane (Figure 15), the ratio between glucose and galactose changed and the ribose peak disappeared, indicating (in agreement with PAGE data) removal of RNA and its fragments.

(d) Amino acid composition:

25 The free amino acids contained in the extracts were determined as follows: The samples were dissolved in distilled de-ionized water for a final concentration of 10 mg/mL. To 25 µL (250 µg) of each sample, 75 µL of Beckman sample buffer (Na-S) was added. Samples were centrifuged at 16,000 x g to 30 remove particulate matter before analysis on the Beckman Model 6300 amino acid analyser. The centrifugation clarified the

solution and the pellet was retained; the supernatant was analysed for free amino acids.

To determine the amino acid composition of whole hydrolysates, portions of each sample (250 µg) were placed into 5 a cleaned glass test tube along with the internal standard norleucine and 1 mL 6N HCl. The tubes were sealed under vacuum and the peptides and polypeptides hydrolysed at 105°C for 20 hours. The tubes were opened and the samples were dried in a Savant Environmental Speed-vac at room temperature. The 10 residues were re-dissolved in Na-S buffer and handled as described above for the determination of free amino acids.

(e) DNA content:

The *Chlorella* extract was dissolved in distilled water (500 µL). An equal volume of a phenol / chloroform / 15 isoamyl alcohol (25:24:1, v/v) solution is added. The mixture is shaken vigorously then centrifuged at 13,000 rpm for 5 minutes. The top aqueous layer is pipetted off and re-extracted with an additional 500 µL of the organic mixture. The aqueous layer is re-extracted until the protein layer (a 20 visible interface between the aqueous and organic layers) is negligible. After the final protein extraction, the aqueous layer was transferred to a fresh tube and to it was added glycogen (10 µL), 3M sodium acetate (50 µL), and cold ethanol (1 mL). The mixture was shaken and placed in the -80°C freezer 25 for an hour. It was then centrifuged at 13,000 rpm for 15 minutes and the supernatant was poured off. The pellet was dried on the speed-vacuuming and re-dissolved in water. Its absorbance was measured at 260 nm against a water blank. Since 30 proteins also absorb at 260 nm, protein absorbance readings at 280 nm were also taken as a measure of protein content in the DNA sample.

Example 7: Enzyme digestion of extracts

Enzyme degradation was used as a technique to selectively eliminate various macromolecular classes from the Chlorella extracts. IBP-2 or its fractions (both IBP-2 and its 5 fractions are designated ONC-107 in this example) were treated with pronase, DNase, RNase, amylase, amyloglucosidase, cellulase and neuraminidase in separate experiments. SDS page and agarose electrophoresis as well as thin layer chromatography were used to monitor the enzymatic reactions 10 (see sections (a) to (g) below). The final reaction mixtures were dialyzed, lyophilized and tested for the capacity to stimulate undifferentiated spleen cells by thymidine incorporation into murine splenocytes (Examples 9 and 11). The results are summarized as follows:

- 15 • No effect on the capacity to stimulate undifferentiated spleen cells within a statistical significance after treatment with the selected enzymes.
- 20 • No presence of large molecular mass RNA in IBP-2. This is in agreement with other findings (above), specifically that no ribose was found in high molecular mass species (IBP-5, IBP-7) and in fractions ultrafiltered with MWCO > 1 MDa. This clearly demonstrates that RNA is not the primary 25 source of the immunostimulating activity.
- 30 • A very small quantity of DNA was found, which is in accord with our data obtained from the isolation of DNA using a silicon carbide column (about 2% content, 500 bp) (see Haj-Ahmad Y (1999) Nucleic acid purification and process. Canadian published application 2,270,106).

All enzyme digestions were performed in parallel with positive controls to ensure that the enzymes were active. The experiments clearly indicate that unassociated, enzyme-accessible protein and nucleic acids are unlikely to be sources 5 of the activity. The source of immunoactivity is a polysaccharide (perhaps complexed with another biopolymer which has no significant effect by itself and which might have an indirect role, e.g. stability). The immunoactivity of the polysaccharide is not affected by cleavages in the regions of 10 three or more α -1,4-linked D-glucose units, α -1,4-linked glucosides and galactosides, or α -1,4-linked D-glucose, assuming such linkages are accessible to enzyme cleavage.

(a) Protease Treatment

Protease (100 μ g/ml, *Streptomyces griseus*) was added 15 to ONC-107 (20 mg/ml) in TRIS buffer (0.05M, pH 7.4) and incubated for 1 hour at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. Aliquots were taken from the solution at time intervals of 0, 5, 10, 15, 30 20 and 60 minutes and prepared for analysis by SDS-PAGE electrophoresis (12% gel, total protein stain). The optimum concentration of protease was determined by a similar electrophoretic time course involving BSA (1mg/ml). The final digest mixture was analyzed by agarose electrophoresis 25 (1% stained with ethidium bromide).

(b) DNAse Treatment

DNAse (100 μ g/ml) was added to ONC-107 (20mg/ml) in TRIS buffer (0.05M, pH 7.4, 10mM MgCl₂) and incubated for 1 hour 30 at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. The final digest mixture was analyzed

by SDS-PAGE electrophoresis (12% gel, total protein stain) to check for protein degradation. Agarose electrophoresis (1% stained with ethidium bromide) was used to confirm nucleic acid degradation.

5 (c) RNAse Treatment

RNAse (100 μ g/ml) was added to ONC-107 (20mg/ml) in TRIS buffer (0.05M, pH 7.4, 10mM NaCl) and incubated for 1 hour at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. The final digest mixture was analyzed by SDS-PAGE electrophoresis (12% gel, total protein stain) to check for protein degradation. Agarose electrophoresis (1% stained with ethidium bromide) was used to confirm nucleic acid degradation.

15 (d) Amylase Treatment

Amylase (100 μ g/ml) was added to ONC-107 (20mg/ml) in TRIS buffer (0.05M, pH 7.4) and incubated for 1 hour at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. The final digest mixture was analyzed by SDS-PAGE electrophoresis (12% gel, total protein stain) to check for protein degradation. Agarose electrophoresis (1% stained with ethidium bromide) was used to confirm nucleic acid degradation.

Additionally, thin layer chromatography (TLC) confirmed the activity of the enzyme as follows. Amylase (100 μ g/ml) was added to a solution of starch (1mg/ml) and incubated for one hour at 36°C. The solution was analyzed via TLC using keisgel silica plates eluted with isopropanol:ethylacetate:water (7:1:2). The plates were developed after 10 minutes drying in the horizontal position using a sulfuric acid/ethanol solution. Glucose (1mg/ml) was

used as a control as was untreated starch. Treatment of starch with amylase resulted in the liberation of glucose.

(e) Amyloglucosidase

Amyloglucosidase (100 μ g/ml) was added to ONC-107 (20mg/ml) in TRIS buffer (0.05M, pH 4.4) and incubated for 1 hour at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. TLC confirmed the activity of the enzyme as follows. Amyloglucosidase (100 μ g/ml) was added to a solution of starch (1mg/ml) and incubated for one hour at 36°C. The solution was analyzed via TLC using keisgel silica plates eluted with isopropanol:ethylacetate:water (7:1:2). The plates were developed after 10 minutes drying in the horizontal position using a sulfuric acid/ethanol solution. Glucose (1mg/ml) was used as a control as was untreated starch. Treatment of starch with the amyloglucosidase resulted in the liberation of glucose.

(f) Cellulase

Cellulase (100 μ g/ml) was added to ONC-107 (20mg/ml) in TRIS buffer (0.05M, pH 7.4) and incubated for 1 hour at 36°C. Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. TLC confirmed the activity of the enzyme as follows. Cellulase (100 μ g/ml) was added to a solution of cellulose (1mg/ml) and incubated for one hour at 36°C. The solution was analyzed via TLC using keisgel silica plates eluted with isopropanol:ethylacetate:water (7:1:2). The plates were developed after 10 minutes drying in the horizontal position using a sulfuric acid/ethanol solution. Glucose (1mg/ml) was used as a control as was untreated cellulose.

Treatment of cellulose with cellulase resulted in the liberation of glucose.

(g) Neurominidase

Neurominidase ($100\mu\text{g}/\text{ml}$) was added to ONC-107
5 (20mg/ml) in TRIS buffer (0.05M, pH 5.0) and incubated for 1 hour at 36°C . Incubation was stopped by heat deactivation of the enzyme at 80°C for 1 hour followed by centrifugation for 10 minutes at 13000 rpm. TLC confirmed the activity of the enzyme as follows. Neurominidase (100ug/ml) was added to a
10 solution of N-acetyl-neuromidose (1mg/ml) and incubated for one hour at 36°C . The solution was analyzed via TLC using keisgel silica plates eluted with isopropanol:ethylacetate:water (7:1:2). The plates were developed after 10 minutes drying in the horizontal position using a sulfuric acid/ethanol solution.

15 Example 8: Stimulation of splenocyte proliferation.

Fresh splenocyte cells (splenocyte primary culture) were plated at 3×10^5 cells/well in cRPME medium in a 100 μl volume in 96-well flat bottom tissue culture plates. Test samples in 100 μl of cell medium were added to triplicate wells
20 giving a final total volume in each well of 200 μl . The plates were covered with sterile lids and incubated in 5% CO_2 at 37°C and 100% humidity in a CO_2 incubator for 48 h. The cells were then pulsed with ^3H -thymidine (1 μCi per well in 10 μl cRPME) and incubated for 18 h. Cells were harvested with an automated
25 cell harvester equipped with filter strips. The filter strips were allowed to dry for 3 h at 37°C . The radioactivity incorporated by the cells was determined by counting the filter strips immersed in scintillation medium in a liquid scintillation counter. An example of the experiment is
30 illustrated in Figure 7. A comparison of applicant's extract with two commercial samples is illustrated in Figure 13.

Example 9: Isolation of B-cells and T-cell from splenocytes and stimulation of the cells

Mouse splenocytes were isolated by routine methods and placed in tissue culture flasks at 37°C for 2 hr, to allow
5 the macrophages to settle and adhere to the flask. The lymphocytes (which are suspended and do not adhere) are then removed and placed in a 50 ml centrifuge tube, spun and resuspended in a small amount of cold PBS-EDTA-BSA buffer (pH 7.4; 1-3 ml) and placed on ice. Cells were counted and
10 recentrifuged. They were then resuspended at 1×10^8 in 0.3 ml of the PBS-EDTA-BSA buffer in a 15 ml centrifuge tube.

Negative isolation of B-cells: 100 μ l of Miltenyi microbeads coated with anti-Thy-1.2 antibody was added to the resuspended cells, and the mixture was incubated for
15 20 minutes. PBS-EDTA-BSA (5mL) was added and the suspension was pipetted into a midiMACS column in a midiMACS magnet. The column had a 25-gauge needle on the outflow to restrict the flow rate. The T-cells, bound to the anti-Thy-1.2 antibody-coated magnetic beads, adhered to the column. The B-cells
20 passed through and were collected. The column, without being removed from the magnet, was rinsed with 5 ml of the buffer to remove any residual B-cells. The B-cells were combined, spun, resuspended in 1 ml of cRPME and counted. They were then resuspended to 5×10^6 cells per ml of cRPME and plated at
25 100 μ l/well for stimulation assays.

Negative isolation of T-cells: The same procedure was followed as for isolation of B-cells, except the magnetic beads used for the incubation were coated with anti-B220 antibody instead of anti-Thy-1.2.

30 The purified T- and B-cell populations were tested as described in Example 8. The results are shown in Figure 8.

Example 10: Nitrite Assay for mouse peritoneal macrophages.

Mice were euthanized by cervical dislocation, and placed spadeagled on their backs. Their abdomens were sterilized with 70% alcohol, and a careful midline incision exposing the INTACT peritoneal wall was made. A 10 -ml syringe was used to inject 10 ml of cold cRPMI-1640 into the mouse peritoneal cavity. The mice were gently rocked from side to side with the needle still inserted. The cRPMI-1640 containing the peritoneal macrophages was slowly drawn from the peritoneal cavity through the needle. About 8 ml of fluid per mouse was recovered. The peritoneal fluid was pooled and put into 50 mL centrifuge tubes on ice. The cells were spun down, washed and resuspended in 1 ml of cRPMI-1640. After counting, they were resuspended to $1\text{-}2 \times 10^6$ cells/ml and plated into a 96-well tissue culture plate at 1×10^5 cells/well in a 100 μl volume. Test samples were added in cRPMI (100 μl) with and without IFN- μ . The positive controls were the cells + IFN- μ and LPS + IFN- μ . The cells were incubated for 48 h in a CO₂ incubator in 5% CO₂.

Fifty μl of the culture fluid was collected and transferred to wells in a 96-well flat bottom ELISA plate. Twofold serial dilutions of NaNO₂ (125 μM to 1 μM final concentration) in cRPMI were made, and 50 μl of each Greiss Reagent solution and the NaNO₂ dilutions were added to a set of wells to provide a standard curve. Absorbance at 550 nm was measured and a plot of absorbance values against NaNO₂ concentrations was made. The standard curve was used to determine the amount of NO₂⁻ produced by the peritoneal macrophage samples. An example of the experiment is illustrated in Figure 9.

Example 11: Determination by sandwich ELISA of stimulation of cytokine production by mouse splenocytes

Cytokine production was measured in mouse splenocytes, in separated mouse T- and B-lymphocytes, and in 5 mouse macrophages. The test samples were added at several concentrations to the cells in microtiter tissue culture plates. After incubating for 24-48 h, depending on the cytokine of interest, the supernatant culture fluid was removed for ELISA.

10 ELISA plates were coated with anti-cytokine monoclonal antibodies by incubation at 4°C overnight in a carbonate buffer, pH 9.6. The plates were then washed with Tris-buffered saline (TBS), post-coated with 2 mg/ml BSA in TBS, (200 µl/well) for 2 h at room temperature and washed with 15 TBS/Tween. The samples and standards (the latter diluted 1 ng/ml to 15 pg/ml in twofold dilutions) were diluted in TBS/Tween containing 1 mg/ml BSA (100 µl/well), added to the plate, incubated overnight at 4°C and then washed with TBS-Tween.

20 The appropriate biotinylated anti-cytokine mAb (0.5 µg/ml) in PBS-Tween containing 1 mg/ml BSA (100 µl/well), was added. The plate was incubated at room temperature for 1 h and then washed with TBS-Tween. Extravidin-Peroxidase in PBS-Tween containing 1 mg/ml BSA (100 µl/well) was added and 25 incubated at room temperature for 30 minutes. The plates were then washed. One hundred µl/well of TMB substrate solution was added, and after 10 to 30 minutes, depending on color development, the reaction was stopped with 100 µl/well of 1 M H₃PO₄. The plate was read at 450 nm. An example of stimulation 30 of IL-6 production is illustrated in Figure 10.

Example 12: Effect of IBP-2 on proliferation of *Listeria monocytogenes* in infected mice

Two doses of IBP-2 (0.1 mg or 4 mg) or plain water (negative control) were administered to Balb/c mice by 5 intragastric tube three times a week for four weeks. The mice were then infected by intravenous injection of 5,000 viable *Listeria monocytogenes* organisms. Three days after the *Listeria* injections, the mice were sacrificed. Cell suspensions of their spleens were made and cultured on culture 10 dishes to determine the number of bacteria in the spleens. The water-fed animals had 92,202 ($\pm 23,000$) bacterial colony forming units (CFUs) in their spleens; (the number in bracket refers to the standard deviation). The animals fed 0.1 mg of IBP-2 per dose had 43,310 ($\pm 7,021$) CFUs and the animals fed 4 mg of IBP-2 15 per dose had only 5,317 (± 492) CFUs ($p < 0.05$) (Figure 11).

Example 13: Effect of IBP-2 on proliferation of *Candida albicans* in infected mice

IBP-2 (4 mg), crude algae (4 mg or 20 mg), or plain water was administered to Balb/c mice by intragastric tube 20 3 times per week for two weeks. The mice were then infected by intravenous injection of 500,000 viable *Candida albicans* organisms. Feeding continued until the mice were sacrificed 12 days after infection. The kidneys were removed and cell suspensions made and cultured on Sabouraud agar to determine 25 the number of *C. albicans* colonies which developed overnight. The following results were obtained: water fed mice 594 (± 556) colonies (mean \pm standard deviation); IBP-2 (4 mg) fed mice 42 (± 75) ($p < 0.05$ compared to water fed mice); algae (4 mg) fed mice 335 (± 663); algae (20 mg) fed mice 79 (± 70); 30 (statistically, the p value for this group compared to the water fed group was > 0.05 , although it was very close to being significant). The results are illustrated in Figure 12.

Example 14: Phase 2 clinical trial study

This study was designed to assess the immuno-stimulatory efficacy of Chlorella extracts as a nutritional supplement in healthy adults over 50 years of age. A 5 first-in-man study was completed which demonstrated the safety and tolerability of a Chlorella extract corresponding to IBP-1 when given as a once daily supplement over three weeks. This purpose of this phase 2 study was to increase the human 10 experience with Chlorella extracts through increased safety and tolerability assessment and to explore the capacity of Chlorella extracts as an immune stimulating nutritional supplement in humans.

The study was designed as a randomized, placebo controlled clinical trial in which adults 50 years of age or 15 older were assigned by chance to receive a 200 mg capsule of a Chlorella extract corresponding to IBP-1, (designated ONC-107 for the purpose of this study), a 400 mg capsule of ONC-107, or a placebo capsule (containing no ONC-107). While the trial was underway, the investigators, the nurses and other study 20 personnel and the participants were not aware to which group they were assigned. The safety and side effects were measured by careful recording by the participant of any adverse event and reporting these to study personnel. Specific adverse events measured included fever, abdominal pain, nausea, 25 vomiting, diarrhea, fatigue, decreased appetite, headache, body aches, sore joints, and rash. Safety was also measured by a series of blood tests before starting the study capsules and at the completion of the study capsules. These tests included tests of liver function (AST, ALT), blood profiles (complete 30 blood count), and immunological function (ANA, anti-DNA, rheumatoid factor, Coombs, C3, C4, quantitative IgG, IgA, IgM, and IgE). Medication was taken for 28 days; after 21 days, participants were immunized with a commercially available,

inactivated, split virion influenza vaccine. Antibody response to the immunization was assessed by measuring antibodies to the three influenza virus strains before, and 7 and 21 days after immunization. Cell mediated immunity was measured by 5 evaluating the response to an influenza skin test at the beginning of the study and one week after the immunization.

A total of 124 subjects were enrolled into the study and took the study medication; 7 participants withdrew from the study. Only one participant withdrew because of adverse events 10 (nausea and abdominal pain). The three treatment groups were similar in age, gender and baseline history and physical examination at the commencement of the study. The majority of participants were women (73.2-80.5% of each group).

Participant compliance was excellent. Antibody response to the 15 influenza vaccine was not significantly higher in the ONC-107 treated participants overall although in participants 55 years of age or younger there was a significantly enhanced response to some antibody measures (and a consistent trend to the others). There were no serious adverse events in any of the 20 study participants. An adverse event was reported by most participants at sometime during the study but, for the most part, these events were not reported more frequently in the ONC-107 recipients compared to the placebo recipients (fatigue was reported more frequently by 200 mg ONC-107 recipients and 25 abdominal pain more frequently by placebo recipients older than 55 years of age). There were no significant changes in laboratory measurements before and after therapy, or between recipients of the ONC-107 and placebo.

The results of this phase 2 study of the nutritional 30 supplement ONC-107 at doses of 200 mg and 400 mg for 28 days in healthy adults are outlined below. They indicate that, despite an age effect, this product is well tolerated and safe for oral administration and has a measurable immunostimulatory effect.

The immunostimulatory effect was measured by antibody response to influenza vaccine in healthy adults over 50 years of age, although these responses were in general limited to the younger cohort in the study population (50-55 years of age).

- 5 The increase in antibody response in this subgroup was statistically significant for some of the comparisons but the trend was apparent in all serological comparisons made. The pre-study hypothesis that the effect of ONC-107 would be best observed in the older subjects because of their decreased 10 responsiveness to influenza vaccine was not supported by the data; in contrast, it was the younger, more responsive subjects who demonstrated an effect of the ONC-107.

The younger subjects tended to show immunostimulatory effects of ONC-107 (especially 400 mg dose). A potential 15 reason for the lack of effect in the older age group was that the older group may have had higher pre-immunization antibody titers which may indicate a greater degree of prior exposure to antigenically similar flu virus A strains (but not the B strains).

20 1. For the A/Caledonia strain of the flu vaccine, the younger (<=55yrs.) age group had higher mean antibody titers with both doses than placebo at both 7 (not significant at 7 d) and 21 days ($p=0.05$): placebo=43.2; 200mg=84.3; 400mg=84.4.

25 2. For the B/Yamanashi strain of the flu vaccine, the 400mg group had higher titers (30.1) at 7 days vs. placebo (14.4, $p=0.03$), but this was not significant at 21 days. The 200mg dose was not significantly greater than placebo at 7 days (15.9) or 21 days (25.3).

30 3. For A/Panama strain of the flu vaccine, there was a similar trend in favour of 400mg dose, but it was not

significant. At 7 days, the 400mg group had titers of 64.5, compared to placebo (39.9), which is not significant. The 200mg group has titers of 26.6. At 21 days, there was also a trend in favour of 400mg vs. placebo; again, 200mg was not 5 better than placebo (57.4).

Similar trends were observed for the proportion of subjects having 2- and 4-fold antibody responses.

For the B/Yamanashi in the <55yr. group, only 5% of the placebo had a 2-fold antibody response at 7 days. This is 10 in contrast with the 400 mg group (41.2%, p=0.01) and 200 mg group (6.3%, p=0.04).

There was also a non-significant trend for an increased response at 21 days, and a non-significant trend in the proportion of the <55yr. age group achieving seroprotective 15 levels of 40 RD (reciprocal dilutions) at 7 days post-immunization.

Numerous modifications, variations and adaptations may be made to the particular embodiments of the invention described above without departing from the scope of the 20 invention which is defined in the claims.